GlaxoSmithKline and Idenix Pharmaceuticals sign worldwide license agreement for IDX899, a novel NNRTI for the treatment of HIV
GSK & Idenix announced agreement granting GSK exclusive worldwide rights to IDX899, a NNRTI in Phase II, treatment of HIV/AIDS.
Read the full articleYou might also wanna read
Novo Nordisk pens long-acting GLP-1 implant tech deal with Vivani Medical
As Novo Nordisk looks for new ways to broaden its semaglutide GLP-1 franchise, the Danish drugmaker has signed a new deal with Californian m
Viking Therapeutics (NASDAQ: VKTX) Faces Uphill Battle In $150 Billion GLP-1 Race Toward 2030
Viking Therapeutics (NASDAQ: VKTX) is positioning itself as a challenger in the obesity drug market, competing directly against industry tit
GSK agrees $10 billion deal for Nuvalent cancer drugs
Deal includes two late-stage molecules to augment GSK’s renewed cancer therapy pipeline
GSK acquires cancer drug developer Nuvalent in $10.6 billion deal
Biotech firm is developing small molecules for lung cancers
cen.acs.org·29d ago
ADA 2026: New GLP-1 Oral Drug, Semaglutide-Amylin Combo, and Chinese Mazdutide Data Highlighted
This Medical News article is an interview with Rita Kalyani, MD, MHS, the American Diabetes Association’s chief scientific and medical offic
ja.ma·20d agoNovo Nordisk: Schritt für Schritt
Der dänische Biopharma-Riese Novo Nordisk bringt seinen Appetitzügler Wegovy (Semaglutid) in immer mehr Ländern auf den Markt. Kein Wunder,
Comments
Sign in to join the conversation.
No comments yet. Be the first.